The Rheumatology Unit, Hadassah Medical Organization, The Faculty of Medicine, Hebrew University of Jerusalem, Israel.
The Pulmonology Unit, Hadassah Medical Organization, The Faculty of Medicine, Hebrew University of Jerusalem, Israel.
Clin Exp Rheumatol. 2023 Mar;41(2):316-321. doi: 10.55563/clinexprheumatol/970881. Epub 2023 Feb 23.
Higher-level evidence is required to discern whether the incidence of idiopathic inflammatory myopathies (IIM) has increased during the COVID-19 pandemic and whether the disease pattern and course have changed. We aimed to analyse patients who were diagnosed with IIM at our tertiary care centre during the pandemic and compare them with IIM patients diagnosed before COVID-19.
We retrospectively analysed the medical records of adult patients (>18 years) who were diagnosed with IIM during COVID-19 versus a control group of patients diagnosed before the outbreak. Included were patients whose diagnosis was made at the Department of Medicine and Rheumatology Unit of Hadassah Medical Center, Jerusalem, Israel. We also conducted a comprehensive review of the literature regarding SARS-CoV-2 infection and vaccine-induced IIM.
Our study yielded 18 and 16 diagnosed IIM patients over periods of 27 and 56 months in the COVID-19 and pre-pandemic cohorts, respectively. These constitute incidence rates of 0.66 and 0.28 patients/month, respectively, marking an increased rate in the COVID-19 group. Unique features were noted in IIM patients who were diagnosed during the pandemic. This includes male predominance (M:F ratio of 12:6), higher hospitalisation rate (0.77 vs. 0.43 admitted/total patients) and increased number of patients with CPK >10,000 U/L (3 vs. 1 patient). Despite the more severe presentation and course in the pandemic group, survival was comparable between the groups.
The incidence of IIM increased during the COVID-19 pandemic. These patients display unique features and a more severe presentation. Fortunately, the prognosis remains unchanged.
需要更高层次的证据来确定特发性炎症性肌病（IIM）在 COVID-19 大流行期间的发病率是否增加，以及疾病模式和病程是否发生变化。我们旨在分析在我们的三级保健中心诊断为 IIM 的患者，并将其与 COVID-19 之前诊断的 IIM 患者进行比较。
我们回顾性分析了在 COVID-19 期间在以色列耶路撒冷哈达萨医疗中心医学系和风湿病科诊断为 IIM 的成年（>18 岁）患者的病历，并将其与大流行前的对照组患者进行比较。包括在该部门诊断出的患者。我们还对 SARS-CoV-2 感染和疫苗诱导的 IIM 的文献进行了全面综述。
我们的研究在 COVID-19 组和大流行前组中分别获得了 27 个月和 56 个月期间诊断出的 18 例和 16 例 IIM 患者。这分别构成了 0.66 和 0.28 例/月的发病率，表明 COVID-19 组的发病率增加。在大流行期间诊断出的 IIM 患者中注意到了独特的特征。这包括男性患病率高（男女比为 12:6），住院率更高（0.77 比 0.43/总患者），以及更多的肌酸磷酸激酶（CPK）>10,000 U/L 的患者（3 比 1 例）。尽管大流行组的表现和病程更为严重，但两组的生存率相当。
在 COVID-19 大流行期间，IM 的发病率增加。这些患者表现出独特的特征和更严重的表现。幸运的是，预后保持不变。
